Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Clinical trial NCT02898116 · COMPLETED
Trial details
- NCT number
- NCT02898116
- Sponsor
- Ludwig Institute for Cancer Research
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-10
- Primary completion
- 2017-08-04
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.